This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Because of its aggressive nature, MCL is typically treated with combination chemotherapy at diagnosis. November 21, 2019. For this application, the FDA collaborated with the Australian Therapeutic Goods Administration, Health Canada, and Switzerland’s Swissmedic. healthbook TIMES Onco Hema. 2024;22(4):22-29. doi:10.36000/HBT.OH.2024.22.163
December 12, 2019. How your oncology peers manage the complexities of care. Oncology Live ®. December 13, 2018. Accessed May 15, 2025. Desimone R. Improve work performance with a focus on employee development. Updated January 19, 2024. Accessed May 15, 2025. LinkedIn Workplace Learning Report 2024. LinkedIn Learning. Accessed May 15, 2025.
Find out more J&J’s drug is an option for patients where medical or surgical treatment to lower testosterone levels has not worked, and in those who have BRCA 1/2 mutations – a subset of homologous recombination repair (HRR) mutations – in whom chemotherapy is not indicated.
ADCs continue to possess the potential to provide a more impactful benefit to patients than chemotherapy alone, with a more limited toxicity profile. All patients in the study had progressed following platinum-based chemotherapy, and 90% of patients had progressed after immune checkpoint inhibitors. and 30% from China. mg/kg, 1.2
The other scenario involved treatments that were more expensive, but no more effective than alternatives, such as the Abraxane chemotherapy. The researchers examined Medicare beneficiaries who were diagnosed with cancer and received treatment from 2014 through 2019.
But Bristol stumbled in 2016 when its immunotherapy Opdivo failed to help patients with non-small cell cancer more than chemotherapy. In 2019, Caforio tried to flip the script, buying the biotech Celgene for $74 billion. STAT recently sat down with Caforio, 59, to look back on what went wrong and right with his tenure.
After the brain tumor diagnosis in 2016, Gatton would undergo two brain surgeries, radiation treatment, chemotherapy, followed by an embryo transfer that failed. But after all that, another embryo transfer had worked, and in fall 2019, Gatton was expecting. Read the rest…
Although not new, drug shortages are now a crisis, with an increasing number of reports about cancer doctors having to ration chemotherapies and other drugs. At the request of a large bipartisan group of lawmakers, a task force chaired by the Food and Drug Administration in 2019 reported on the root causes of drug shortages.
China’s Shanghai Henlius Biotech says its experimental PD-1 inhibitor serplulimab has extended survival when added to chemotherapy in a phase 3 trial as first-line therapy for extensive stage small cell lung cancer (ES-SCLC), setting up regulatory filings.
The two companies have been working together since 2019 on digital health interventions to provide support to people with cancer, focusing initially on tools for patients undergoing cancer immunotherapy.
Keytruda has been approved since 2016 as a second-line option after chemotherapy for patients with more advanced disease, i.e. recurrent or relapsed HNSCC that has metastasised to other parts of the body.
.” Hopes were high that a drug developed by Sangamo based on its zinc finger nuclease (ZFN) genome-editing technology could lead to the first therapy that could correct the genetic defect n MPS I, but that candidate – called SB-318 – flunked out in a clinical trial reported in 2019 and was discontinued.
Chemotherapy still accounted for 72.6% of the oncology market in China in 2019, compared to 17.1% million in 2019, and are estimated to increase to 5.7 Chemotherapy still plays a significant role in oncology treatment, accounting for 72.6% of the oncology market in China in 2019, compared to 17.1% million in 2030.
Kaiku’s DPPM platform has also attracted the attention of other big pharma groups, including Roche which has been working with the company since 2019 on personalised support modules for patients taking its PD-L1 inhibitor Tecentriq (atezolizumab).
MCL is generally treated first with chemotherapy, and patients whose disease progresses despite that can then receive stem cell transplantation or BTK inhibitor drugs like Johnson & Johnson/AbbVie’s Imbruvica (ibrutinib) and AstraZeneca’s Calquence (acalabrutinib).
The HDAC inhibitor was given an accelerated approval by the FDA as a second-line PTCL therapy on the strength of overall response data, but a phase 3 study comparing Istodax to first-line chemotherapy showed no improvement on progression-free survival (PFS).
The UK Medicines and Healthcare products Regulatory Agency (MHRA) granted conditional approval for Retsevmo (selpercatinib) as monotherapy for adults with advance RET fusion-positive non-small cell lung cancer requiring systemic therapy after previous immunotherapy and/or chemotherapy treatment.
Alexion teamed up with Caelum on CAEL-101 in 2019, taking a minority stake in the company, and the partners advanced the drug into the phase 3 CARES programme last year. Each year, an estimated 4,500 people develop AL amyloidosis in the US alone, and there are an estimated 30,000 to 45,000 people living with the disease in the US and Europe.
Rozlytrek was approved by the FDA in 2019 but has just started to gather sales momentum, making around $17 million in the first quarter of this year, an increase of 78% on the first three months of 2021. Another research note from SVB Securities predicted that repotrectinib could eventually become a $1.5
Today's approval amends the accelerated approval granted by the FDA in April 2019 to Balversa (erdafitinib) for patients with metastatic urothelial carcinoma with susceptible FGFR2 or FGFR3 alterations following prior treatment with platinum-containing chemotherapy.
The review will mainly look at AZ and Daiichi Sankyo’s DESTINY-Lung01, a phase 2 trial which showed a 55% overall response rate for Enhertu in patients previously treated with platinum chemotherapy, mainly partial responses, with a median duration of response of just over 9 months. billion licensing deal for the drug in 2019.
AstraZeneca’s blood-cancer treatment portfolio already includes Calquence (acalabrutinib), a chemotherapy-free monotherapy for patients with chronic lymphocytic leukaemia (CLL). . The transaction is expected to close in the third quarter of 2022, subject to customary closing conditions and regulatory clearances.
To recap, Padcev (enfortumab vedotin) was quickly okayed by the FDA in December 2019 in advanced urothelial cancer on the basis of phase 2 response data that made it a rising star at that year’s American Society of Clinical Oncology (ASCO) conference. months in the chemotherapy group. of patients in the chemotherapy arm.
Until now people with AL amyloidosis have had to rely on chemotherapy, with its accompanying side effects, and other drugs to tackle organ failure once damage gets severe. Darzalex Faspro looks set to transform the prospects for the 30,000 to 45,000 people in the US and Europe AL amyloidosis patients.
Novel device opens blood-brain barrier to deliver chemotherapy Intratumoural delivery The current trial was designed to evaluate the combination of intratumoural DNX-2401 followed by intravenous pembrolizumab therapy. The study enrolled 49 patients with recurrent GBM from several institutions between September 2016 to January 2019.
The SKYSCRAPER-02 showed that the combination of the two drugs given on top of chemotherapy was unable to improve progression-free survival versus Tecentriq (atezolizumab) plus chemo in extensive-stage SCLC – a notoriously hard-to-treat form of lung cancer.
Today (27 April), the ODAC is due to look at Tecentriq in combination with BMS/Celgene’s Abraxane (nab-paclitaxel) for people with advanced triple-negative breast cancer (TNBC) whose tumours express PD-L1, an indication which was provisionally approved by the FDA in 2019 on the strength of the Impassion130 study.
Sobi acquired Doptelet via its $915 million takeover of Dova Pharmaceuticals in 2019, adding to its haematology and rare disease franchise. The European approval of Doptelet as a second-line treatment for ITP after therapies such as corticosteroids and immunoglobulin drugs comes after a green light by the FDA in July 2019.
. “This is welcome news for my patients, many of whom have already benefitted from the extra time this treatment gives them, without the need for chemotherapy,” said Dr Mark Verrill, a consultant medical oncologist at Newcastle upon Tyne Hospitals NHS Foundation Trust.
Boston, US-based Alexion spent a lot of 2019 arguing the merits of remaining independent, saying that while Soliris is approaching the end of its patent life – with heavyweight competitors like Amgen already eyeing the biosimilar market for the drug – Ultomiris and its pipeline could help drives sales to $9 to $10 billion in 2025.
On March 27, MSD announced that the combined use of Keytruda with chemotherapy significantly improved progression-free survival versus the chemotherapy alone, as a first-line therapy for advanced or recurrent endometrial carcinoma. This announcement is not the only recent development for Keytruda.
How do you perceive radiopharmaceuticals complementing existing cancer treatments, such as chemotherapy and immunotherapy? There is great hope of this class of drug specifically to work in conjunction with immunotherapeutics, given the lack of toxicity of radiopharmaceuticals in general compared to most chemotherapies.
The latest disappointment has come from the phase 2 INTR@PID BTC 055 study of the drug alongside chemotherapy as a first-line treatment for patients with locally advanced or metastatic biliary tract cancer (BTC), which has been abandoned early. billion deal signed in 2019 that kicked off with a $363 million upfront payment.
GSK paid $360 million upfront in 2019 for a stake in bintrafusp alfa – a bifunctional fusion protein that targets PD-1 and TGF-beta – but Merck confirmed in a statement that it had no received any milestone payments from the alliance, which had been valued at up to $4.2 billion takeover of Tesaro in 2019.
It’s the second acquisition in just a few weeks for Withings , which launched an electrocardiogram (ECG) enabled smartwatch in 2019 in a bid to take on market leader Apple, and also sells ‘smart’ scales and thermometers, blood pressure monitors, and sleep-tracking mattresses.
GSK snapped up rights to bintrafusp alfa in 2019, paying around $360 million upfront for a global stake in the drug – a bifunctional fusion protein that targets PD-1 and TGF-beta. The hypothesis that hitting both targets could boost the number of patients responding to PD-1 immunotherapy and the depth of that response is now looking shaky.
Sources Community-acquired urinary tract Infection by Escherichia coli in the era of antibiotic resistance , BioMed Research International (2018) Urinary tract infection , Centers for Disease Control and Prevention (2021) Amoxicillin , StatPearls (2022) Uncomplicated urinary tract infections , StatPearls (2023) Beta-lactam antibiotics , StatPearls (..)
In 2019, Daiichi Sankyo entered a global development and commercialisation agreement with AstraZeneca for Daiichi Sankyo’s lead antibody-drug conjugate (ADC), Enhertu (trastuzumab deruxtecan), in a deal worth $6.9bn. months compared with patients treated with standard-of-care chemotherapy.
Treatment, for example, chemotherapy and radiotherapy. Sci Rep 9, 17648 (2019). Published 2019 Jun 29. One of the most common reasons for dry mouth is dehydration. Other common reasons for dry mouth include: Taking certain drugs (see the next paragraph). Underlying conditions, for example, diabetes or Sjögren’s syndrome.
The drug was first approved in TNBC in 2019 and there few alternatives for treatment of this aggressive form of the disease. The last few months have seen four occasions in which drugmakers have opted to voluntarily withdraw approvals for cancer drugs that failed confirmatory trials.
Xencor has previously partnered with MorphoSys and Incyte to test plamotamab in combination with their CD19-targeted antibody Monjuvi (tafasitamab) – plus Bristol-Myers Squibb’s Revlimid (lenalidomide) – as a chemotherapy-free strategy for relapsed or refractory diffuse large B-cell lymphoma (DLBCL), an aggressive type of NHL.
COSTAR is comparing Jemperli plus cobolimab and docetaxel chemotherapy to Jemperli/docetaxel and docetaxel alone in advanced NSCLC patients whose cancer has progressed after first-line PD-1/PD-L1 inhibitor therapy. billion deal agreed in 2019, along with PARP inhibitor Zejula (niraparib).
We organize all of the trending information in your field so you don't have to. Join 5,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content